Form 4: Amneal Pharmaceuticals Director Equity Transaction

Director J. Kevin Buchi acquired 34,819 shares of Amneal Pharmaceuticals via restricted stock unit vesting and received a new grant of 19,824 units.

Summary

• Director J. Kevin Buchi exercised 34,819 restricted stock units (RSUs) on May 7, 2026, which converted into Class A Common Stock.
• The reporting person was granted an additional 19,824 RSUs on May 6, 2026.
• Following these transactions, the director holds 75,077 shares directly and 262,072 shares indirectly through a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation and ownership changes.

Positives

• Director maintains significant skin in the game with over 337,000 total shares held.
• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• None identified; this is a standard compensatory equity transaction.

Risks

• Standard market risks associated with pharmaceutical equity holdings.

Future Outlook

The newly granted 19,824 restricted stock units are scheduled to vest on the later of the day preceding the first annual meeting following the grant or the first anniversary of the grant date.

Management Comments

• Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Industry Context

StockSavvy.ai notes that routine equity vesting for board members is standard practice in the pharmaceutical sector to ensure long-term alignment between governance and corporate performance.

Comparison to Industry Standards

• The transaction follows standard SEC Section 16 reporting requirements for public company directors.
• Equity compensation structures are consistent with peer pharmaceutical companies of similar market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director compensation.

Next Steps

• Vesting of the 19,824 newly granted restricted stock units subject to the terms of the grant agreement.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Insider Trading, Form 4, Equity Compensation, Director Ownership